MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1572-0241.2002.07111.x

Медицинская библиотека · The American journal of gastroenterology · 2002

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

Olden Kevin, DeGarmo Ronald G, Jhingran Priti, Bagby Barbara, Decker Chris, Markowitz Michael, Carter Eric, Bobbitt William, Dahdul Adnan, DeCastro Enrique, Gringeri Louis, Johanson John, Levinson Lawrence, Mula Gregory, Poleynard Gary, Stoltz Randall R, Truesdale Richard, Young Douglas, Lotronex Investigator Team

Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials. However, the degree to which alosetron fulfills the needs of those suffering from IBS has not been thoroughly examined from the patient's perspective. This randomized, double-blind, placebo-controlled study conducted in women with diarrhea-predominant IBS evaluated patients' overall satisfaction with treatment as well as their satisfaction with respect to several specific medication attributes.

METHODS

Patients randomized to receive either alosetron 1 mg b.id. (n = 532) or placebo (n = 269) were administered a questionnaire on which they rated on 7-point Likert scales their prestudy IBS treatment (at the screening visit) or study medication (on wk 12 or final study visit) with respect to overall satisfaction and 11 specific medication attributes.

RESULTS

Whereas approximately 10% of patients were satisfied or very satisfied overall with prestudy IBS medication, 69% of patients were satisfied or very satisfied overall with alosetron and 46% with placebo (p < 0.001) at the end of 12 wk of therapy. The majority of alosetron-treated patients (61-87%) were satisfied or very satisfied with each of 11 specific medication attributes (p < 0.001 vs placebo for each attribute). Favorable satisfaction ratings for alosetron were assigned to the five medication attributes that patients considered to be most important, including relief of urgency (68% alosetron vs 41% placebo), speed of relief (71% vs 40%), time to return to normal activities (75% vs 49%), relief of abdominal pain (62% vs 44%), and prevention of return of urgency (68% vs 42%).

CONCLUSIONS

Women with diarrhea-predominant IBS are satisfied with alosetron 1 mg b.i.d. treatment overall and also with respect to specific attributes of IBS medication they consider most important.

Для цитирования: Olden Kevin, DeGarmo Ronald G, Jhingran Priti, Bagby Barbara, Decker Chris, Markowitz Michael, Carter Eric, Bobbitt William, Dahdul Adnan, DeCastro Enrique, Gringeri Louis, Johanson John, Levinson Lawrence, Mula Gregory, Poleynard Gary, Stoltz Randall R, Truesdale Richard, Young Douglas, Lotronex Investigator Team. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.. The American journal of gastroenterology. 2002. DOI: 10.1111/j.1572-0241.2002.07111.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.